Anjing Chen

Dr. Anjing Chen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JJJianxiong Ji
Jianxiong Ji
RXRan Xu
Ran Xu
KDKaikai Ding
Kaikai Ding
Guoqing BaoGuoqing Bao
Guoqing Bao
XZXin Zhang
Xin Zhang
JWJian Wang
Jian Wang
Purpose: Long noncoding RNAs (lncRNAs) have essential roles in diverse cellular processes, both in normal and diseased cell types, and thus have emerged as potential therapeutic targets. A specific member of this family, the SWI/SNF complex antagonist associated with prostate cancer 1 (SChLAP1), has been shown to promote aggressive prostate cancer growth by antagonizing the SWI/SNF complex and therefore serves as a biomarker for poor prognosis. Here, we investigated whether SChLAP1 plays a potential role in the development of human glioblastoma (GBM). Experimental Design: RNA-ISH and immunohistochemistry were performed on a tissue microarray to assess expression of SChLAP1 and associated proteins in human gliomas. Proteins complexed with SChLAP1 were identified using RNA pull-down and mass spectrometry. Lentiviral constructs were used for functional analysis in vitro and in vivo. Results: SChLAP1 was increased in primary GBM samples and cell lines, and knockdown of the lncRNA suppressed growth. SChLAP1 was found to bind heterogeneous nuclear ribonucleoprotein L (HNRNPL) which stabilized the lncRNA and led to an enhanced interaction with the protein actinin alpha 4 (ACTN4). ACTN4 was also highly expressed in primary GBM samples and was associated with poorer overall survival in glioma patients. The SChLAP1-HNRNPL complex led to stabilization of ACTN4 through suppression of proteasomal degradation, which resulted in increased nuclear localization of the p65 subunit of NF-κB and activation of NF-κB signaling, a pathway associated with cancer development. Conclusions: Our results implicated SChLAP1 as a driver of GBM growth as well as a potential therapeutic target in treatment of the disease.

11 July 2022 in Theranostics
Verified
Journal Article
Open access
XWXu Wang
Xu Wang
MHMingzhi Han
Mingzhi Han
SWShuai Wang
Shuai Wang
YSYanfei Sun
Yanfei Sun
WZWenbo Zhao
Wenbo Zhao
JWJian Wang
Jian Wang
Background: Splicing factors are essential for nascent pre-mRNA processing and critical in cancer progression, suggesting that proteins with splicing functions represent potential molecular targets for cancer therapy. Here, we investigate the role of splicing factors in glioblastoma multiforme (GBM) progression and the possibility of targeting them for the treatment of the disease.

1 February 2024 in Medicinal Research Reviews
Verified
Journal Article
Closed access
JWJialong Wu
Jialong Wu
JHJide He
Jide He
ZLZenan Liu
Zenan Liu
XZXuehua Zhu
Xuehua Zhu
ZLZiang Li
Ziang Li
JLJian Lu
Jian Lu

21 October 2024 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
WZWenguo Zhao
Wenguo Zhao
JWJiazheng Wang
Jiazheng Wang
FZFeihu Zhao
Feihu Zhao
YLYaquan Li
Yaquan Li
ZLZhuo Li
Zhuo Li
ACAnjing Chen
Anjing Chen
Glioblastoma multiforme (GBM) is a highly heterogeneous brain tumor with limited treatment options. Recent studies revealed cellular heterogeneity and the potential for interconversion between distinct cell types on the basis of RNA sequencing and single-cell analyses. The ability of different cell types to adapt to their surrounding environment and undergo transformation significantly complicates the study and treatment of GBM. In this study, we reveal that HNRNPK-SUMO1 expression is predominantly found in the GBM infiltration area. SUMOylation of the K422 residue of HNRNPK interferes with its DNA binding ability, thereby disrupting downstream transcription, and ultimately leading to transitions between different states of glioblastoma stem cells. Although the proneural subtype is considered to have a better prognosis, transitioning towards this state promotes tumor invasion. These findings serve as a reminder to exercise caution when considering treatments targeting specific cellular subtypes.

8 November 2022 in Journal of Non-Crystalline Solids
Verified
Journal Article
Closed access
FLFufen Li
Fufen Li
YCYining Chen
Yining Chen
MGMin Gong
Min Gong
ACAnjing Chen
Anjing Chen
LLLang Li
Lang Li
ZLZhengjun Li
Zhengjun Li

17 May 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XZXun Zhang
Xun Zhang
ZYZhong Yao
Zhong Yao
ZXZhiyi Xue
Zhiyi Xue
SWShuai Wang
Shuai Wang
XLXuemeng Liu
Xuemeng Liu
ACAnjing Chen
Anjing Chen
Resibufogenin (RB) is a major active ingredient in the traditional Chinese medicine Chansu and has garnered considerable attention for its efficacy in the treatment of cancer. However, the anticancer effects and underlying mechanisms of RB on glioblastoma (GBM) remain unknown. Here, we found that RB induced G2/M phase arrest and inhibited invasion in a primary GBM cell line, P3#GBM, and two GBM cell lines, U251 and A172. Subsequently, we demonstrated that RB-induced G2/M phase arrest occurred through downregulation of CDC25C and upregulation of p21, which was caused by activation of the MAPK/ERK pathway, and that RB inhibited GBM invasion by elevating intercellular Ca2+ to suppress the Src/FAK/Paxillin focal adhesion pathway. Intriguingly, we confirmed that upon RB binding to ATP1A1, Na+-K+-ATPase was activated as a receptor and then triggered the intracellular MAPK/ERK pathway and Ca2+-mediated Src/FAK/Paxillin focal adhesion pathway, which led to G2/M phase arrest and inhibited the invasion of GBM cells. Taken together, our findings reveal the antitumor mechanism of RB by targeting the ATP1A1 signaling cascade and two key signaling pathways and highlight the potential of RB as a new class of promising anticancer agents.